| Literature DB >> 27129719 |
Stephen E Mshana1, Linda Falgenhauer2,3, Mariam M Mirambo4, Martha F Mushi4, Nyambura Moremi4, Rechel Julius4, Jeremiah Seni4, Can Imirzalioglu2,3, Mecky Matee5, Trinad Chakraborty2,3.
Abstract
BACKGROUND: Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae commonly cause infections worldwide. Bla CTX-M-15 has been commonly detected in hospital isolates in Mwanza, Tanzania. Little is known regarding the faecal carriage of ESBL isolates and bla CTX-M-15 allele among humans in the community in developing countries.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27129719 PMCID: PMC4850702 DOI: 10.1186/s12879-016-1527-x
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Profile of Igogo, Mbugani and Kirumba
| Variables | Igogo | Mbugani | Kirumba |
|---|---|---|---|
| Population size | 27,303 | 39,041 | 29,354 |
| Number of hospitals/Dispensaries | 2 | 5 | 4 |
| Number of pharmacy/Medicine shops | 18 | 10 | 4 |
| Population per pharmacy/medicine shops | 1516.8 | 3904.1 | 7338.5 |
| Industrial activities | • Industrial areas | • None | • Car garages |
| Type of toilets | Latrines | Latrines | Latrines |
| Damping ground | Present | Present | Present |
| Distance from Tertiary hospital (Bugando Medical Centre) | 1.56 km | 2.16 km | 3.82 km |
| ESBL rates | 20.5 % | 15.2 % | 11.6 % |
Resistance rates of ESBL and Non-ESBL isolates to TET, CIP, CN and SXT
| Antibiotic | NON-ESBL ( | ESBL ( | Total ( |
|
|---|---|---|---|---|
| Tetracycline | 119 (42.7 %) | 44 (80 %) | 163 (48.8 %) |
|
| Ciprofloxacin | 6 (2.1 %) | 37 (67.2 %) | 43 (12.9 %) |
|
| Gentamicin | 14 (5.2 %) | 34 (61.8 %) | 48 (14.4 %) |
|
| Co-trimoxazole | 184 (66.6 %) | 52 (94.5 %) | 216 (64.7 %) |
|
SXT Trimethoprim/sulphamethoxazole, TET tetracycline, CN gentamicin and CIP ciprofloxacin
Predictors of ESBL carriage among 334 humans in the community in Mwanza, city
| Variables | Positive ESBL carriage (55) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| OR (95 % CI) |
| OR (95 % CI) |
| ||
| Age(years)a | 17 (IQR 6–17) | 1.02 (1.2–1.3) | 0.028 | 1.07 (1.04–1.10) | <0.001 |
| Number of childrena | 4 (IQR 2–5) | 1.34 (1.14–1.57) | <0.001 | 1.15 (0.95–1.39) | 0.134 |
| Sex | |||||
| Male (138) | 22 (15.9 %) | 1 | |||
| Female (196) | 33 (16.8 %) | 1.06 (0.94–1.72) | 0.828 | 1.33 (0.67–2.63) | 0.410 |
| Location | |||||
| Kirumba (112) | 13 (11.6 %) | 1 | |||
| Mbugani (66) | 10 (15.2 %) | 1.35 (0.49–3.59) | 0.49 | ||
| Igogo (156) | 32 (20.5 %) | 1.9 (1.0–4.2) | 0.05 | 1.33 (0.901–1.97) | 0.149 |
| Antibiotic use | |||||
| Yes (208) | 44 (21.2 %) | 1 | |||
| No (126) | 11 (8.7 %) | 2.8 (1.38–5.6) | 0.004 | 27 (6.63–116) | <0.001 |
| Admission history | |||||
| No (325) | 49 (15.1 %) | 1 | |||
| Yes (9) | 6 (66.7 %) | 11.3 (2.7–46.5) | 0.001 | 7.4 (1.43–38.5) | 0.017 |
amedian
Resistance genes, sequence types and plasmid replicons of the sequenced isolates
| Isolate | Beta-Lactam genes | Other antibiotic resistance genes | Plasmid replicon type | pMLST | Sequence type | Phylogenetic group |
|---|---|---|---|---|---|---|
| RA005 |
|
| IncFIA, IncFIB, IncFII | F1:A1:B1 | ST-648 | D |
| RA023 |
|
| IncY | - | ST-4450 | A |
| RA025 |
|
| IncY | - | ST-4450 | A |
| RA034 |
|
| IncFIA, IncFIB, IncFII | F1:A1:B1 | ST-648 | D |
| RA043 |
|
| IncY | - | ST-2852 | B1 |
| RA045 |
|
| IncFIA, IncFIB, IncFII | F1:A1:B1 | ST-648 | D |
| RA051 |
|
| IncFIA, IncFIB, IncFII | F31:A4:B1 | ST-617 | A |
| RA061 |
| aadA1, aac(6’)Ib-cr, aac(3)-IIa,strA, strB | IncFIB, IncFII | F1:A-:B33 | ST-38 | D |
| RA073 |
| aadA5, aac(6’)Ib-cr, aac(3)-IIa,strA, strB | IncFIA, IncFIB, IncFII | F1:A1:B16 | ST-131 | B2 |
| RA085 |
|
| IncFIA, IncFIB, IncFII, IncY | F1:A1:B20 | ST-2852 | B1 |
| RA102 |
|
| IncFIB, IncFII | F1:A-:B33 | ST-38 | D |
| RA105 |
| aadA5, aac(6’)Ib-cr, aac(3)-IId, strA,strB | IncFIA, IncFIB, IncFII | F87:A4:B1 | ST-617 | A |
| RA116 |
|
| IncFIB, IncFIA, IncQ1, IncFII | F1:A1:B16 | ST-131 | B2 |
| RA134 |
|
| No replicon | ST-205 | B1 | |
| RA166 |
|
| IncFIA, IncFIB, | F31:A4:B1 | ST-131 | B2 |
| RA173 |
|
| IncFIB, IncFIA, IncQ1, IncFII | F48:A1:B26 | ST-131 | B2 |
| RA175 |
|
| IncFIA, IncFIB, IncQ1, IncFII | F48:A1:B26 | ST-131 | B2 |
| RA176 |
|
| IncY | - | ST-38 | D |
| RA194 |
|
| IncFIA, IncFIB, IncFII | F31:A4:B1 | ST-617 | A |
| RA195 |
|
| IncFIB, IncFII | F1:A-:B33 | ST-38 | D |
| RA217 |
| aadA5, aac(6’)Ib-cr,aac(3)-IIa, strA, strB | IncFIA, IncFIB, IncFII | F31:A4:B1 | ST-44 | A |
| RA218 |
|
| IncFIB, IncFIA, IncFII | F31:A4:B1 | ST-44 | A |
| RA228 |
|
| IncFIB, IncFII | F1:A-:B33 | ST-38 | D |
| RA246 |
| aadA5, aac(6’)Ib-cr, aac(3)-IIa, strA,strB | IncFIA, IncFII | F2:A1:B- | ST-131 | B2 |
| RA256 |
|
| IncY, IncFIB | F46:A-:B24 | ST-2852 | B1 |
in these isolates CTX-M-15 was located in the chromosome
Fig. 1Phylogenetic tree of 25 ESBL-producing E. coli based on the whole genome rooted from E. coli MG1655 genome. The tree was produced using Harvest Suite and drawn by MEGA5 software
Virulence factors in relation to ST and phylogenetic group
| Isolate | Sequence type | Phylogroup | Virulence gene |
|---|---|---|---|
| RA005 | ST-648 | D |
|
| RA023 | ST-4450 | A |
|
| RA025 | ST-4450 | A |
|
| RA034 | ST-648 | D |
|
| RA043 | ST-2852 | B1 |
|
| RA045 | ST-648 | D |
|
| RA051 | ST-617 | A |
|
| RA061 | ST-38 | D |
|
| RA073 | ST-131 | B2 |
|
| RA085 | ST-2852 | B1 |
|
| RA102 | ST-38 | D |
|
| RA105 | ST-617 | A |
|
| RA116 | ST-131 | B2 |
|
| RA134 | ST-205 | B1 |
|
| RA166 | ST-131 | B2 |
|
| RA173 | ST-131 | B2 |
|
| RA175 | ST-131 | B2 |
|
| RA176 | ST-38 | D |
|
| RA194 | ST-617 | A |
|
| RA195 | ST-38 | D |
|
| RA217 | ST-44 | A |
|
| RA218 | ST-44 | A |
|
| RA228 | ST-38 | D |
|
| RA246 | ST-131 | B2 |
|
| RA256 | ST-2852 | B1 |
|
gad, Glutamate decarboxylase; iss, increased serum survival; iha, adherence protein; sat, secreted autotransporter toxin; IpfA, long polar fimbriae; nfaE, diffuse adherence fimbriae; ireA, siderophore receptor; senB, plasmid encoded enterotoxin; cnf1, cytotoxic necrotizing factor